Cantor Fitzgerald Starts Cara Therapeutics (CARA) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- Comstock Resources signs $1.65B deal with SOCAR, $450M JV
Janney Capital Resumes Cara Therapeutics (CARA) at Buy
November 4, 2015 7:54 AM ESTJanney Capital resumes coverage on Cara Therapeutics (NASDAQ: CARA) with a Buy rating and a price target of $28.00.
Analyst Ken Trbovich commented, "We believe enrollment in CARA's first proof-of-concept study of oral CR845 is now complete. This places CARA on track to... More
